FinTechFunding

LeadArt Biotechnologies: Completes US$6M Pre-A Financing

LeadArt Biotechnologies Completes US$6M Pre-A Financing

  • LeadArt Biotechnologies, a Boston, MA and Ningbo, China-based biotechnology company focused on drug discovery by automating chemoproteomics processes, raised US$6M in Pre-A funding
  • The round was led by BlueRun Ventures Aster
  • The company intends to use the funds to advance the development of its automated chemoproteomics platform and the creation of a human target-probe database
  • LeadArtBiotechnologies is accelerating drug discovery by automating chemoproteomics processes and creating a human live-cell target-probe database
  • Its platform integrates biotechnology and automation technologies to discover disease-related targets and chemical probes for traditionally undruggable and unexplored targets.
Previous article
Vianova: Raises €6M in Series A Funding
Next article
PointsBet: Launches online operations in Ohio
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

Italy Fines Revolut €1.15M for Regulatory Violations

Revolut faces penalties due to non-compliance with Italian financial regulations.Highlights: Italy fines Revolut €1.15 million for regulatory breaches.The...
FinTech

DeFi Platform Drift Suspends Withdrawals After Crypto Hack

Drift takes precautionary measures following security breach affecting user funds.Highlights: Drift has suspended all deposits and withdrawals after...
FinTech

Cross River Bank Raises $50 Million to Accelerate Growth

The funding will enhance Cross River Bank's financial technology services.Highlights: Cross River Bank has raised $50 million in...
FinTech

Kulipa Secures $62M to Enhance Stablecoin Card Issuing Infrastructure

Funding aims to strengthen cryptocurrency card services in the growing fintech market.Highlights: Kulipa raises $62M to enhance its...